Loading...

Home
ETF
EYPT

EYPT

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

EYPT News

EYPT Options Trading Analysis and Strategies

Feb 03 2026NASDAQ.COM

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

Dec 31 2025Benzinga

EyePoint CEO Jay Duker to Present at 2026 J.P. Morgan Healthcare Conference

Dec 17 2025Globenewswire

EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards

Dec 16 2025Globenewswire

EyePoint Grants 137,000 Stock Options to New Employees as Inducement Awards

Dec 16 2025Newsfilter

Market Update: Health Care Stocks Show Varied Performance Ahead of Wednesday's Opening Bell

Nov 19 2025Yahoo Finance

EyePoint Receives Favorable Endorsement from Independent Data Safety Monitoring Committee for Key Phase 3 Trials of DURAVYU™ in Wet Age-Related Macular Degeneration

Nov 19 2025Newsfilter

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Consensus Predictions Have Deteriorated Slightly Following Its Recent Report

Nov 09 2025Yahoo Finance

RBC Capital Reaffirms Outperform Rating for EyePoint Pharmaceuticals and Increases Price Target to $39

Nov 06 2025Benzinga

EyePoint to Present at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 06 2025Newsfilter

EyePoint Completes Enrollment of Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration

Jul 29 2025Newsfilter

Forecasting The Future: 4 Analyst Projections For EyePoint Pharmaceuticals

Jun 17 2025Benzinga

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jun 16 2025Newsfilter

Analyst Expectations For EyePoint Pharmaceuticals's Future

May 29 2025Benzinga

Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday

May 28 2025Benzinga

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 16 2025Newsfilter